Journal
SCIENCE ADVANCES
Volume 2, Issue 9, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.1601017
Keywords
-
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-15208]
- Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) [Progetto Bandiera Epigenomica (EPIGEN)]
- IIT-Sapienza Project
- AIRC-Fondazione Cariplo TRIDEO [17515]
- PRIN [prot. 2012CTAYSY]
- FP7 [BLUEPRINT/282510, A-PARADDISE/602080]
- Armenise-Harvard Foundation
- MIUR
- European Community [7551, 10205]
Ask authors/readers for more resources
Because of its involvement in the progression of several malignant tumors, the histone lysine-specific demethylase 1 (LSD1) has become a prominent drug target in modern medicinal chemistry research. We report on the discovery of two classes of noncovalent inhibitors displaying unique structural features. The antibiotics polymyxins bind at the entrance of the substrate cleft, where their highly charged cyclic moiety interacts with a cluster of positively charged amino acids. The same site is occupied by quinazoline-based compounds, which were found to inhibit the enzyme through a most peculiar mode because they form a pile of five to seven molecules that obstruct access to the active center. These data significantly indicate unpredictable strategies for the development of epigenetic inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available